IL21 and neoplasm: A study of ICs hu14.18-IL2/IL15/IL21 in combination with chemotherapy showed that hu14.18-IL15 and hu14.18-IL21 could induce complete tumor regression and improved survival compared with hu14.18-IL2, and their application contributed to an increase in CD8+ T cells and M1 and a decrease in Treg and MSDC in the tumor (166).